Carbapenem Resistance in Clonally Distinct Clinical Strains of *Vibrio fluvialis* Isolated from Diarrheal Samples

Goutam Chowdhury, Gururaja Perumal Pazhani, Anirban Sarkar, Krishnan Rajendran, Asish K. Mukhopadhyay, Mihir K. Bhattacharya, Amit Ghosh, Thandavarayan Ramamurthy

Carbapenems have been used for many years to treat severe nosocomial *Enterobacteriaceae* infections. The spread of resistance to these drugs among other bacterial families is an emerging problem worldwide, mostly caused by New Delhi metallo-β-lactamase (NDM-1). We screened for the prevalence of NDM-1–expressing enteric pathogens from hospitalized patients with acute diarrhea in Kolkata, India, and identified 27 *Vibrio fluvialis*–harboring bla<sub>NDM-1</sub> (NDM-VF) strains. These isolates were also resistant to all the tested antimicrobial drugs except doxycycline. The large plasmid of *V. fluvialis* harboring bla<sub>NDM-1</sub> could be easily transferred to other enteric pathogens. Genes flanking the bla<sub>NDM-1</sub> were found to be identical to the reported sequence from an *Escherichia coli* isolate. Analyses showed that the *V. fluvialis* possessing the NDM-VF region belonged to different clones. The pathogenicity of *V. fluvialis* to humans and its ubiquitous presence in the environment call for constant monitoring of this species for emerging antimicrobial drug resistance.

The increasing incidence of carbapenem-resistant bacterial infection is a major public health concern (1). Several species of carbapenemase-producing bacteria also display co-resistance to most, if not all, available antibiotic drugs used against different infections, thereby limiting the medication options (1). The novel carbapenemase New Delhi metallo-β-lactamase (NDM-1), encoded by the gene bla<sub>NDM-1</sub>, has been identified in many pathogenic members of the family *Enterobacteriaceae*, which are capable of colonizing hosts and also transfer the bla<sub>NDM-1</sub> gene region to other bacteria. Several of these bacteria have been associated with contaminated hands, food, and water in hospitals, community settings, and in the environment (1). However, reports on the prevalence of bla<sub>NDM-1</sub> among enteric pathogens are relatively fewer.

NDM-1–producing *Klebsiella pneumoniae* was first identified in 2008 in a urine sample from a traveler from Sweden who acquired a urinary tract infection in India (2). Investigations by Kumarasamy et al. (3) led to the initial report of widespread prevalence of NDM-1 in *Escherichia coli* and *K. pneumoniae* strains isolated from several clinical settings in India, Pakistan, and the United Kingdom. Numerous studies in subsequent years reported NDM-1–producing *Enterobacteriaceae* and other bacteria, including *Vibrio cholerae* in many countries (4–7). Recently, several reports on carbapenemase-producing *Enterobacteriaceae* in India have been published (8–10). In unrelated gram-negative bacteria, the presence of the bla<sub>NDM-1</sub> gene has been reported to be associated with several plasmid incompatibility types (e.g., IncA/C, IncF, IncL/M, IncH, or untypeable) or was found integrated into the chromosomes (11). Because the gene bla<sub>NDM-1</sub> located on plasmids is also carrying bacterial growth promoter regions, the possibility of gene transfer to other gram-negative bacteria is very high (12).

*V. fluvialis* is known to be commonly present in many aquatic environments and seafood (13). This organism has been reported as an emerging pathogen associated with cholera-like diarrhea in India and China (14,15). We report the identification and characterization of NDM-1–producing *V. fluvialis* strains isolated from diarrheal fecal samples from patients admitted to the 2 hospitals in Kolkata, India.

**Materials and Methods**

Using systematic active surveillance, we enrolled every fifth hospitalized patient at the Infectious Diseases Hospital (IDH) and B.C. Roy Memorial Hospital for Children (BCH) in Kolkata who had diarrhea or dysentery on 2 randomly selected days of the week during May 2009–September 2013. Diarrhea was defined as ≥3 episodes of loose or liquid stools with or without blood within 24...
hours, accompanied by dehydration, nausea, vomiting, abdominal cramping, fever, chills, muscle aches, and fecal urgency. A questionnaire that collected demographic information, illness onset and symptoms, medical care sought, and food/drink consumed was completed by the patient or a family member. Patients with other associated illness and who used antibiotic drugs before hospitalization were not included in this study.

Fecal specimens were collected in McCartney bottles (KM Enterprises, Kolkata, India) by using sterile catheters or rectal swabs in Cary Blair medium (Difco, Sparks, MD, USA) and were examined within 2 hours for enteric pathogens comprising bacterial, viral, and parasitic pathogens by using a combination of conventional, immunological, and molecular methods (16). Patients were observed until their discharge from the hospital. The patients lived in different areas of the Kolkata Municipal region.

We screened for carbapenem resistance in multidrug-resistant isolates of diarrheagenic E. coli, V. cholerae, V. parahaemolyticus, V. fluvialis, Salmonella spp., and Shigella spp. isolated from these patients. We detected V. fluvialis and bla$_{NDM-1}$ by using simplex PCR with previously described methods, lysis cells as templates (17,18), and Taq DNA polymerase (Roche, Mannheim, Germany). Amplicons were purified by using a QIAquick PCR Purification Kit (QIAGEN, Hilden, Germany) and sequenced by using the ABI BigDye Terminator v3.1 Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA, USA) in an automated DNA sequencer (ABI 3730; Applied Biosystems). Sequences were edited with Lasergene software (DNASTAR, Inc., Madison, WI, USA) and analyzed by using BLAST (http://www.ncbi.nlm.nih.gov/blast).

We tested antibiotic susceptibility according to Clinical Laboratory Standards Institute (CLSI) guidelines (19) using commercially available antibiotic discs (Becton-Dickinson, Sparks, MD, USA) for ampicillin, cefoxitin, ceftriaxone, cefotaxime, cefotaxime/clavulanic acid, ceftazidime, ceftazidime/clavulanic acid, chloramphenicol, erythromycin, gentamicin, nalidixic acid, ciprofloxacin, ofloxacin, norfloxacin, imipenem, streptomycin, azithromycin, tetracycline, and trimethoprim/sulfamethoxazole. We used ceftazidime and cefotaxime to confirm production of extended-spectrum β-lactamase by double-disk synergy test. We determined MICs of imipenem, ciprofloxacin, norfloxacin, ceftazidime, cefotaxime, and cefepime using Etest strips (bioMérieux, Marcy l’Étoile, France) following the CLSI interpretive criteria for Vibrio spp. (20). For noncholera Vibrio spp., the CLSI guidelines lack interpretive criteria for some antibiotic drugs; hence, we used breakpoints for E. coli ATCC 25922, which was used as a control in antimicrobial drug susceptibility testing.

We performed the modified Hodge test on Mueller–Hinton agar (Difco) plates, using E. coli ATCC 25922 as the indicator organism and a 10-μg imipenem disk (21). The modified Hodge test is a phenotypic assay for the detection of carbapenemase enzyme–producing bacteria. This assay is based on the inactivation of a carbapenem by carbapenemase-producing test isolates that facilitate a carbapenem-resistant indicator strain (E. coli ATCC 25922) to spread its growth toward a carbapenem-containing disc along the streak of inoculum of the test isolate. A positive test result produces a cloverleaf-like hollow.

We used the Kado and Liu method (22) to extract plasmid DNA from donors, recipients, and transconjugants and analyzed it by gel electrophoresis using 0.8% agarose. We used a PCR-generated DNA probe by the chemoluminescent method (ECL nucleic acid detection system; GE Healthcare Life Sciences, Buckinghamshire, UK) to make Southern hybridization to confirm the presence of bla$_{NDM-1}$ in the plasmids. Plasmid-mediated transfer of antibiotic resistance from a NDM–positive V. fluvialis isolate (IDH 04744) to E. coli J53 (having dual resistant markers for nalidixic acid and sodium azide [Na-Az$^2$]) was tested on MacConkey agar plates (Difco) containing sodium azide (100 mg/L) and meropenem (5 mg/L). Another plasmid-mediated transfer of antibiotic resistance from a NDM–positive V. fluvialis isolate (IDH 04744) has also been tested with diarrheagenic E. coli, Salmonella spp., and Shigella spp. and V. parahaemolyticus on meropenem (5 mg/L) supplemented MacConkey, xylose lysine deoxycholate, and thiosulfate citrate bile sucrose agar (Difco) plates.

Presence of bla$_{NDM-1}$ in the transconjugants was confirmed by PCR. We used PCR and amplicon sequencing to identify other antibiotic resistance genes (aadB, aadA1, strA, aphA1–la, catA1, bla$_{TEM-9}$, bla$_{OXA-1}$, bla$_{OXA-7}$, bla$_{OXA-9}$, bla$_{SHV}$, bla$_{PSE-4}$, bla$_{CTX-M-3}$, aac(6’)-Ib-cr, and fliR) using lysed cells, primers, and previously described conditions (23). We used published primers to determine integrons and resistance gene cassettes in V. fluvialis isolates by PCR (24). The PCR amplicons were purified and directly sequenced. The identities of the sequences were established through a database search by using BLAST and matched with the reference dfkA1 sequence of V. fluvialis (GenBank accession no. AY605688).

We determined the replicon types of bla$_{NDM-1}$-harboring plasmids from the wild isolates and transconjugants by PCR using published methods (25). Sequencing of the bla$_{NDM-1}$ and its flanking regions were made from a wild isolate of V. fluvialis (IDH 05720) by primer walking. The DNA sequence reported in this study has been deposited in GenBank (accession no. KR733543).

Pulsed-field gel electrophoresis (PFGE) analysis of NotI-digested genomic DNA of bla$_{NDM-1}$–harboring V. fluvialis isolates (NDM-VF) was performed by using a CHEF-Mapper (Bio-Rad Laboratories, Hercules, CA, USA) according to the PulseNet standardized protocol for subtyping of V.
cholerae (26). The PFGE image was captured by using a Gel Doc XR system (Bio-Rad). The PFGE image was normalized by aligning the peaks of the XbaI size standards of Salmonella enterica serovar Braenderup (H9182) in each gel and was analyzed by using BioNumerics software version 4.0 (Applied Maths, Sint-Martens-Latem, Belgium). The similarities between isolates were evaluated by using the cluster analysis with the UPGMA method and the Dice correlation coefficient with a position tolerance of 1.5%.

Results
A total of 115 V. fluvialis were isolated from the acute diarrhea patients (each isolate represent a case), of which 27 (23.5%) were resistant for carabapenem and harbored blaNDM-1. The first blaNDM-1–positive V. fluvialis was isolated on May 16, 2011. The isolation rate of NDM-VF was highest in 2012 (14 isolates), followed by 7 in 2011 and 6 in 2013. The NDM-VF was not detected during 2009–2010. The rest of the pathogens tested in this study were susceptible to carabapenem.

Of the 27 NDM-VF strains, 13 (48.1%) were isolated as the sole pathogen; the remaining were co-pathogens isolated with any other pathogen, such as diarrheagenic E. coli, Shigella spp., Salmonella spp., Campylobacter spp., Giardia lambia, and rotavirus. None of the enteric bacteria identified as co-pathogens had blaNDM-1. Most of the NDM-VF were resistant to ampicillin, ceftriaxone, cefuroxime, cefotaxime, nalidixic acid, norfloxacin, ciprofloxacin, ofloxacin, and streptomycin (100% each), followed by trimethoprim/sulfamethoxazole (96.2%), imipenem (88.8%), gentamycin (74.0%), chloramphenicol (70.3%), and tetracycline (14.8%). However, most of the isolates were susceptible to azithromycin (85%) and doxycycline (100%). Higher MICs were observed for cefotaxime (≥16 mg/L), ceftazidime (≥32 mg/L), cefepime (≥16 mg/L), and cefotetan (≥32 mg/L). In 50% of the NDM-VF, ciprofloxacin MIC was ≥32 mg/L, and for norfloxacin and imipenem the MIC values ranged from 4–32 mg/L (Table 1).

The blaNDM-1–harboring V. fluvialis isolates carried multiple plasmids ranging from 5 kb to 150 kb. In Southern hybridization, the large plasmids extracted from the transconjugants were positive for blaNDM-1. In the transconjugants, only a single plasmid of ≈80–90 kb was detected. The transconjugant (TC-J53) also showed resistance to ampicillin, erythromycin, streptomycin, ceftriaxone, cefotaxime, cefuroxime, and imipenem (MIC 2 mg/L), indicating the possibility that the NDM-1 plasmid also harbored genes encoding resistance to these antibiotics. The transconjugant was susceptible to ciprofloxacin, tetracycline, trimethoprim, chloramphenicol, and azithromycin, suggesting that the genes encoding resistance to these drugs are not carried by the blaNDM-1–harboring plasmid. Most of the other enteric pathogens used as transconjugants showed resistance to ampicillin, ceftriaxone, cefotaxime, and sulfamethoxazole. The transfer frequencies ranged from 1.4 × 10^5 to 8.7 × 10^6 (Table 2).

Class-1 integron was identified in all the NDM-1–positive isolates. In 9 isolates, a 1.6-kb PCR amplicon was obtained with the dihydrofolate reductase gene cassette (dfrA1), which encodes resistance for trimethoprim. Overall, 9 different resistance gene profiles were identified (Table 1). All of the 27 NDM-VF isolates were positive for β-lactamase–encoding genes blaOXA-1, blaOXA-23, and blaOXA-9; streptomycin–encoding gene aadA1; gentamycin–encoding gene aadB; and ciprofloxacin-modifying enzyme-encoding gene aac(6’)/Ib-cr (amino glycoside acetyltransferase). Most NDM-VF isolates had sul1, conferring resistance to sulfonamides (96.2%); strA, conferring resistance to streptomycin (92.6%); and sul3, conferring resistance to sulfonamides (88.8%). The floR gene that encodes resistance to chloramphenicol was found in 20 (74%) of NDM-VF isolates. The other β-lactamase encoding genes, blaTEM-9 and blaCTX-M-2, which confer resistance to ceftriaxone, were detected in 15 (55.5%) isolates. The tetracycline resistance marker gene tet(B) was detected in only 4 isolates (14.8%).

In rep licon typing, plasmids of NDM-VF isolates were untypeable. To gain insight into the genetic background of blaNDM-1, the flanking regions of this gene were examined in a representative V. fluvialis isolate (IDH 04744). The flanking sequences of IDH 04744 V. fluvialis were identical to the ones reported in the E. coli isolates from Hong Kong, China (pNDM-HK; GenBank accession no. HQ451074), and from a Spanish traveler returning from India (DVR22; GenBank accession no. JF922606.1) (Figure 1). The left junction of the sequences starts upstream of the blaNDM-1 with a truncated ISAba125 region, whereas the right junction possessed different genes such as blaBLE (bleomycin resistance encoding gene), trpF, blaNDM-1, and ampR.

Eighteen different patterns that could be grouped into 2 distinct clusters (A–C; Figure 2) were obtained in the PFGE analysis. Most of the isolates in cluster B had ≥90%–100% similarity. Nearly identical PFGE profiles were obtained for 11 isolates (cluster B). These isolates were isolated over a span of 1 year (May 2011–May 2012), without any epidemiologic link. We also found no correlation between the PFGE and antimicrobial drug resistance patterns.

Discussion
Since its discovery, global distribution of blaNDM-1 in different bacterial species has been extensively documented (27). NDM-1 producers are reported not only from patients epidemiologically linked to the Indian subcontinent but also from several indigenous cases all over the world with no such link. Previously, we reported on the emerging trend of V. fluvialis among the diarrheal cases in the Kolkata region (14). However, NDM-VF emerged in Kolkata during
Table 1. Antimicrobial drug resistance genes and MICs of *Vibrio fluvialis* isolates in study of diarrheal fecal samples from patients in Kolkata, India, May 2009–September 2013†

| Isolate no. | Resistance gene profile | MICs, µg/mL |
|-------------|-------------------------|-------------|
|              | IPM | CTX | TAZ | PM | CIP | NOR | CN | TET |
| IDH 03626    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 03631    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 03645    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 03671    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 03679    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| BCH 01733    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 0422     |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 04149    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 04166    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 04169    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 04228    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 04252    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 04325    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 04326    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 04328    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 04414    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| BCH 02360    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 04568    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 04607    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 04744    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 05335    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 05715    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 05720    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 05733    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 05799    |     |     |     |    |     |     |     |     |
|              |     |     |     |    |     |     |     |     |
| IDH 05818    |     |     |     |    |     |     |     |     |

†All isolates were positive in the modified Houge test and susceptible for imipenem with EDTA. CIP, ciprofloxacin; CN, cefotetan; CTX, cefotaxime; IPM, imipenem; ND, not done; NOR, norfloxacin; PM, cefepime; TET, tetracycline; TAZ, cefazidime.

2011, and 25%–50% of the *V. fluvialis* isolates harbored *bla*NDM-1* each year until 2013. It is difficult to epidemiologically link the isolates because of the wide difference in the dates of isolation of NDM-VF, lack of common food sources, and variation in the proximity of the residential area of the patients; antibiogram and PFGE patterns are also widely divergent.

NDM-1 producers have been found to be highly resistant to several classes of antibiotics (28–30), related to their unusual genetic assembly, which helps in the
acquisition and transfer of many resistance genes. Environmental strains of *Aeromonas caviae* and *V. cholerae* were found to carry *bla*<sub>NDM-1</sub> on the chromosomes (12). In contrast, we found that, in NDM-VF, *bla*<sub>NDM-1</sub> is present on the large plasmids.

Generally, the emergence of NDM-1 producers is associated with excessive use of carbapenems in patients with nonintestinal infections that necessitate a prolonged stay in a hospital. However, none of the patients in this study had a history of using carbapenem drugs. Most NDM-VF isolates remained susceptible to azithromycin, which is currently used in the treatment of diarrheal patients in Kolkata.

We found that a large plasmid from NDM-VF was effectively transferred to *E. coli* J53 and other enteric pathogens.

---

### Table 2. Antimicrobial drug resistance profiles before and after transfer of NDM-1—encoding plasmid from *Vibrio fluvialis* strains to other bacterial species in study of diarrheal fecal samples from patients in Kolkata, India, May 2009–September 2013

| Isolate no. | Test isolate | Resistance profile of wild type | Resistance profile of transconjugant | MIC IPM, μg/mL† | Frequency of transfer |
|-------------|--------------|---------------------------------|-------------------------------------|-----------------|-----------------------|
| J53-Na-Azide | *Escherichia coli* | AMP, CRO, SXT, CXM, CTX | AMP, CRO, SXT, CXM, CTX | 3 | 8.7 × 10^5 |
| BCH 04216 | EAEC | AMP, ERY, SXT, NA, CXM, CTX | AMP, E, SXT, NA, CXM, CTX | 3 | 5.9 × 10^5 |
| IDH 04184 | EPEC | AMP, ERY, OFX, SXT, NA, CIP, CRO, CXM, CTX | AMP, E, OFX, SXT, NA, CIP, CRO, CXM, CTX | 1.5 | 2.7 × 10^5 |
| IDH 06412 | ETIE | AMP, ERY, NA, SXT | AMP, E, NA, SXT, CRO, CXM, CTX | 3 | 7.5 × 10^5 |
| BCH 0704 | *Salmonella* Bareilly | ‐ | AMP, CRO, SXT, CTX, CTX | 3 | 1.7 × 10^3 |
| 570764 | *Salmonella* Newport | ‐ | AMP, CRO, SXT, CTX, CTX | 3 | 1.4 × 10^3 |
| IDH 06370 | *Shigella dysenteriae* 12 | AMP, STR, NA | AMP, STR, NA, CRO, SXT, CXM, CTX | 1.5 | 2.4 × 10^3 |
| IDH 06498 | *Shigella flexneri* 4 | AMP, E, STR, SXT | AMP, E, STR, SXT, CRO, CXM, CTX | 3 | 4.4 × 10^3 |
| IDH 06342 | *Shigella flexneri* 1b | AMP, E, NA, STR, SXT | AMP, E, NA, STR, SXT, CRO, CXM, CTX | 0.75 | 1.9 × 10^3 |
| IDH 03988 | *V. parahaemolyticus* | AMP | AMP, CRO, SXT, CXM, CTX | 0.50 | 5.7 × 10^5 |

†Antibiogram in bold among transconjugants denote acquired resistance phenotypes from *V. fluvialis* IDH05720 after conjugation. AMP, ampicillin; CIP, ciprofloxacin; CRO, ceftiraxone; CTX, cefotaxime; CXM, cefuroxime; EAEC, enterotoxigenic *E. coli*; EPEC, enteropathogenic *E. coli*; ERY, erythromycin; ETIE, enterotoxigenic *E. coli*; NA, nalidixic acid; NDM-1, New Delhi metallo-β-lactamase; NOR, norfloxacin; OFX, ofloxacin; STR, streptomycin; SXT, sulfamethoxazole.

†MIC for imipenem. MIC denotes values of imipenem across different pathogens that were used as transconjugants.

---

**Figure 1.** Structural features of *bla*<sub>NDM-1</sub> flanking regions of *Vibrio fluvialis* and other bacterial species in study of diarrheal fecal samples from patients in Kolkata, India, May 2009–September 2013. Arrow lengths are proportionate to the lengths of the genes or open reading frames. GenBank accession numbers are shown. Gene names: *ISAba125*, insertion sequence; *bla*<sub>NDM-1</sub>, New Delhi metallo-β-lactamase; *ble*<sub>Mbl</sub>, bleomycin resistance protein; *trpF*, phosphoribosylanthranilate isomerase; *sbd*, cytochrome c-type biogenesis protein; *groL*, chaperonins; *insE*, transposase insertion sequence; *aadA2*, aminoglycoside adenylytransferase; *dfrA12*, dihydrofolate reductase; *IntI1*, class I integron integrase; *tnpA*, transposition transposase; *ISCR1*, insertion sequence common region; *sul1*, dihydropteroate synthase; *qacE<sub>Δ1</sub>*1, ethidium bromide resistance protein; *aphA6*, aminoglycoside phosphotransferase; *insE<sub>Δ1</sub>*1, Class C β-lactamase; *ampR*, transcriptional regulator; *aacC2*, aminoglycoside acetyltransferase; *iscE28*, transposase; *armA*, 16S rRNA methylase; *hpyA*, putative hydrogenase nickel incorporation protein.
Carbapenem Resistance in *Vibrio fluvialis*

Even though we demonstrated the in vitro transfer of bla<sub>NDM-1</sub> in other enteric bacteria, these bacteria are not completely resistant to carbapenems, as is *V. fluvialis*. Multiple NDM-1–producing pathogens belonging to different species from a patient have been reported (31). Although in our study, 14 of 27 patients were infected with other pathogens (enteroaggressive *E. coli* [EAEC], enterotoxigenic *E. coli* [ETEC], *V. cholerae*, *V. parahaemolyticus*, *Salmonella* spp., *Shigella* spp., and *Campylobacter* spp.), only patients with *V. fluvialis* were found to harbor bla<sub>NDM-1</sub>. The controlling factors that may prevent such transfer in the gut milieu should be explored further.

The resistance profiles of ampicillin, ceftriaxone, trimethoprim/sulfamethoxazole, cefuroxime, and cefotaxime have been transferred to all the transconjugants. This indicates that the bla<sub>NDM-1</sub>–positive isolates may carry similar plasmids with the uniform resistance genes and, hence, confer the same resistance phenotype. Generally, the conjugative plasmids carrying bla<sub>NDM-1</sub> have been classified into several replicon types, including IncA/C, IncFII<sub>Y</sub>, IncHI<sub>B</sub>, IncX3, and IncT (32). However, the NDR-VF isolates were negative for all the NDM-1 plasmids in the PCR-based replicon typing. These results suggest that the NDM-1–encoding genes move with several plasmid scaffolds or as the same Inc type, which might not be covered by the currently used replicon typing scheme of *Enterobacteriaceae*. In many bacterial species from India, the bla<sup>NDM-1</sup>–harboring plasmids were found to belong to A/C-type, an uncommon group for conferring multidrug-resistant phenotypes (3).

Analysis of the genes adjoining the bla<sub>NDM-1</sub> in *V. fluvialis* isolate IDH 04744 revealed a high homology with *E. coli* NDM-HK and DUR-22 (GenBank accession nos. HQ451074 and JF922606) (33, 34). Insertion sequences (IS) IS26 and ISaba125 have been identified upstream of the bla<sub>NDM-1</sub> gene, and these sequences have been reported in other organisms. In most of the NDM-1–positive bacteria, the IS elements are detected in the flanking regions of bla<sub>NDM-1</sub>. We detected the IS26 and ISaba125 in the upstream of the bla<sub>NDM-1</sub> gene. The presence of IS26, ISCR1, and transposases have been increasingly implicated in interspecies and intraspecies dissemination of antimicrobial resistance.
drug resistance genes (35,36). These IS elements probably help in the mobility of bla\textsubscript{NDM-1}.

We also identified the ble\textsubscript{MBL} gene downstream of bla\textsubscript{NDM-1}. In most of the Enterobacteriaceae, bla\textsubscript{NDM-1} has been detected between a truncated IS\textsubscript{Aba125} located upstream and ble\textsubscript{MBL} at the downstream. This genetic arrangement suggests an en bloc acquisition of bla\textsubscript{NDM-1} and ble\textsubscript{MBL} through the IS\textsubscript{Aba125}-related mobilization system. The presence of ble\textsubscript{MBL} appears to be an added advantage to the bla\textsubscript{NDM-1}–positive bacteria, because both genes are expressed under the control of single promoter; therefore, the presence of ble\textsubscript{MBL} may help the bla\textsubscript{NDM-1}–bearing plasmids to spread in other bacterial species (37).

\textit{V. fluvialis} is increasingly being detected in our setting and among diarrheal patients (14). These \textit{V. fluvialis} isolates are capable of readily acquiring antibiotic resistance genes through mobile genetic elements (38). Our findings indicate that \textit{V. fluvialis} might acquire the bla\textsubscript{NDM-1} gene without any antibiotic selective pressure. This pathogen also has the potential to transfer this gene to other enteric pathogens. PCR-based identification of the NDM-1 regions in suspected pathogens will be very useful. The \textit{V. fluvialis} isolates harboring bla\textsubscript{NDM-1} are mostly susceptible to doxycycline and azithromycin. Considering the pathogenicity of \textit{V. fluvialis} to humans and its ubiquitous presence in the environment, the need for constant monitoring of this \textit{Vibrio} species is ongoing.

Acknowledgments

We thank George A. Jacoby, Lehey Hospital and Medical Center, Burlington, MA, USA, for kindly providing the \textit{Escherichia coli} JS3 (Az2) strain.

This work was funded by the Indian Council of Medical Research. The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. A.G. is an India National Science Academy Senior Scientist attached to the National Institute of Cholera and Enteric Diseases in Kolkata.

G.C., G.P.P., A.G., and A.K.M. isolated and identified the pathogens and performed phenotypic characterization and all genetic analysis. K.R. and M.K.B. analyzed the clinical data and provided the specimens. T.R.M. and A.G. conceived the study and wrote the manuscript. All authors were involved in the compilation of the report and approved the final version.

Dr. Chowdhury is a postdoctoral researcher at the Division of Bacteriology, National Institute of Cholera and Enteric Diseases, Kolkata, India. His research interest includes the molecular epidemiology of antimicrobial drug resistance, with emphasis on enteric pathogens.

References

1. Nordmann P, Poirel L, Walsh TR, Livermore DM. The emerging NDM carbapenemases. Trends Microbiol. 2011;19:588–95. http://dx.doi.org/10.1016/j.tim.2011.09.005
2. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, et al. Characterization of a new metallo-beta-lactamase gene, \textit{bla}\textsubscript{NDM-1}, and a novel erythromycin esterase gene carried on a unique genetic structure in \textit{Klebsiella pneumoniae} sequence type 14 from India. Antimicrob Agents Chemother. 2009;53:5046–54. http://dx.doi.org/10.1128/AAC.00774-09
3. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10:597–602. http://dx.doi.org/10.1016/S1473-3099(10)70143-2
4. Dortet L, Poirel L, Nordmann P. Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria. Biomed Res Int. 2014;2014:249856.
5. Darley E, Weeks J, Jones L, Daniels V, Wootton M, MacGowan A, et al. NDM-1 polymicrobial infections including \textit{Vibrio cholerae}. Lancet. 2012;380:1358. http://dx.doi.org/10.1016/S0140-6736(12)60911-8
6. Ghosh A, Sarkar A, Chowdhury G, Pazhani GP, Ramamurthy T. Overview on the New Delhi metallo-beta-lactamase (NDM)-producers. Proc Indian Natn Sci Acad. 2014;80:547–63. http://dx.doi.org/10.16943/ptmsa/2014/v80i3/55132
7. Diop TT, Nguyen NT, Nguyen TN, An HK, Nguyen TQ, Nguyen VH, et al. Isolation of New Delhi metallo-beta-lactamase 1-producing \textit{Vibrio cholerae} non-O1, non-O139 strain carrying \textit{crpA}, \textit{st} and \textit{hly} genes in southern Vietnam. Microbiol Immunol. 2015;59:262–7. http://dx.doi.org/10.1111/1348-0421.12248
8. Sarma JB, Bhattacharya PK, Kalita D, Rajbangshi M. Multidrug-resistant \textit{Enterobacteriaceae} including metallo-beta-lactamase producers are predominant pathogens of healthcare-associated infections in an Indian teaching hospital. Indian J Med Microbiol. 2011;29:22–7. http://dx.doi.org/10.4103/0255-0857.67519
9. Bora A, Ahmed GU, Hazarika NK, Prasad KN, Shukla SK, Randhawa V, et al. Incidence of \textit{bla}_{NDM-1} gene in \textit{Escherichia coli} isolates at a tertiary care referral hospital in Northeast India. Indian J Med Microbiol. 2013;31:250–6. http://dx.doi.org/10.4103/0255-0857.115628
10. Menon T, Kumar VN, Sekar M, Princy A. NDM-1 producers as causative agents of nosocomial urinary tract infections. Indian J Med Microbiol. 2013;31:219–20. http://dx.doi.org/10.4103/0255-0857.115674
11. Pillai DR, McGeer A, Low DE. New Delhi metallo-beta-lactamase-1 in \textit{Enterobacteriaceae}: emerging resistance. CMAJ. 2011;183:59–64. http://dx.doi.org/10.1503/cmaj.101487
12. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis. 2011;11:355–62. http://dx.doi.org/10.1016/S1473-3099(11)70059-7
13. Ramamurthy T, Chowdhury G, Pazhani GP, Shinoda S. \textit{Vibrio fluvialis}: an emerging human pathogen. Front Microbiol. 2014;5:91. http://dx.doi.org/10.3389/fmicb.2014.00091
14. Chowdhury G, Pazhani GP, Dutta D, Guin S, Dutta S, Ghosh S, et al. \textit{Vibrio fluvialis} in patients with diarrhea, Kolkata, India. Emerg Infect Dis. 2012;18:1806–7. http://dx.doi.org/10.3201/eid1811.120520
15. Liang P, Cui X, Du X, Kan B, Liang W. The virulence phenotypes and molecular epidemiological characteristics of \textit{Vibrio fluvialis} in China. Gut Pathog. 2013;5:6. 10.1186/1757-4749-5-6 http://dx.doi.org/10.1186/1757-4749-5-6
16. Panchalingam S, Antonio M, Hossain A, Mandomando I, Ochieng BJ, Oundo J, et al. Diagnostic microbiologic methods
Carbapenem Resistance in Vibrio fluvialis

in the GEMS-lasace/control study. Clin Infect Dis. 2012;55(suppl 4):S294–302. http://dx.doi.org/10.1093/cid/cis754

17. Chakraborty R, Sinha S, Mukhopadhyay AK, Asakura M, Yamasaki S, Bhattacharya SK. Species-specific identification of Vibrio fluvialis by PCR targeted to the conserved transcriptional activation and variable membrane tether regions of the toxR gene. J Med Microbiol. 2006;55:805–8. http://dx.doi.org/10.1099/jmm.0.46395-0

18. Chen Y, Zhou Z, Jiang Y, Yu Y. Emergence of NDM-1 producing Acinetobacter baumannii in China. J Antimicrob Chemother. 2011;66:1255–9 http://dx.doi.org/10.1093/jac/dkr082

19. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests; approved standard, 12th edition (M02–A12). Wayne (PA): The Institute; 2015.

20. Clinical and Laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria, 3rd edition (M45). Wayne (PA): The Institute; 2015.

21. Carvalhaes CG, Picao RC, Nicoletti AG, Xavier DE, Gales AC. Cloverleaf test (modified Hodge test) for detecting carbapenemase production in Klebsiella pneumoniae: be aware of false positive results. J Antimicrob Chemother. 2010;65:249–51. http://dx.doi.org/10.1093/jac/dkp431

22. Kado CI, Liu ST. Rapid procedure for detection and isolation of large and small plasmids. J Bacteriol. 1981;145:1365–73.

23. Maynard C, Fairbrother JM, Bekal S, Sanschagrin F, Levesque RC, Brousseau R, et al. Antimicrobial resistance genes in enterotoxigenic Escherichia coli O149:K91 isolates obtained over a 23-year period from pigs. Antimicrob Agents Chemother. 2003;47:3214–21. http://dx.doi.org/10.1128/AAC.47.10.3214-3221.2003

24. Dalsgaard A, Forslund A, Serichantalergs O, Sandvang D. Distribution and content of class 1 integrons in different Vibrio cholerae O-serotype strains isolated in Thailand. Antimicrob Agents Chemother. 2000;44:1315–21. http://dx.doi.org/10.1128/AAC.44.5.1315-1321.2000

25. Carattoli A, Miriagou V, Bertini A, Loli A, Colinson C, Villa L, et al. Replicon typing of plasmids encoding resistance to newer beta-lactams. Emerg Infect Dis. 2006;12:1145–8.

26. Cooper KL, Luey CK, Bird M, Terajima J, Nair GB, Kam KM, et al. Development and validation of a PulseNet standardized pulsed-field gel electrophoresis protocol for subtyping of Vibrio fluvialis. Foodborne Pathog Dis. 2006;3:51–8. http://dx.doi.org/10.1089/fpd.2006.3.51

27. Poirel L, Hombrouck-Alet C, Freneaux C, Bernabeu S, Nordmann P. Global spread of New Delhi metallo-β-lactamase 1. Lancet Infect Dis. 2010;10:832. http://dx.doi.org/10.1016/S1473-3099(10)70279-6

28. Bush K. New β-lactamases in Gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis. 2001;32:1085–9. http://dx.doi.org/10.1086/319610

29. Rolain JM, Parola P, Cornaglia G. New Delhi metallo-β-lactamase (NDM-1): towards a new pandemia? Clin Microbiol Infect. 2010;16:1699–701. http://dx.doi.org/10.1111/j.1469-0691.2010.03385.x

30. Nordmann P, Poirel L, Toleman MA, Walsh TR. Does broad-spectrum β-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J Antimicrob Chemother. 2011;66:689–92. http://dx.doi.org/10.1093/jac/dka520

31. Huang YM, Zhong L, Zhang XF, Hu HT, Li YQ, Yang XR, et al. NDM-1-producing Citrobacter freundii, Escherichia coli and Acinetobacter baumannii identified from a single patient in China. Antimicrob Agents Chemother. 2015;59:5073–7. http://dx.doi.org/10.1128/AAC.04682-14

32. Villa L, Poirel L, Nordmann P, Carta C, Carattoli A. Complete sequencing of an IncH plasmid carrying the blaNDM-1, blaCTX-M-15 and qnrB1 genes. J Antimicrob Chemother. 2012;67:1645–50. http://dx.doi.org/10.1093/jac/dks114

33. Ho PL, Lo WU, Yeung MK, Lin CH, Chow KH, Ang I, et al. Complete sequencing of pNDM-HK encoding NDM-1 carbapenemase from a multidrug-resistant Escherichia coli strain isolated in Hong Kong. PLoS One. 2011;6:e17989. http://dx.doi.org/10.1371/journal.pone.0017989

34. Solé M, Pitart C, Roca I, Fabrega A, Salvador P, Muñoz L, et al. First description of an Escherichia coli strain producing NDM-1 carbapenemase in Spain. Antimicrob Agents Chemother. 2011;55:4402–4. http://dx.doi.org/10.1128/AAC.00642-11

35. Toleman MA, Bennett PM, Walsh TR. ISCR elements: novel gene capturing systems of the 21st century? Microbiol Mol Biol Rev. 2011;75:463–95. http://dx.doi.org/10.1128/MMBR.00048-05

36. Shahid M. Citrobacter spp. simultaneously harboring blaCTX-M, blaTEM, blaSHV, blaOXY, and insertion sequences IS26 and orf513: an evolutionary phenomenon of recent concern for antibiotic resistance. J Clin Microbiol. 2010;48:1833–8. http://dx.doi.org/10.1128/JCM.01467-09

37. Dorlet L, Nordmann P, Poirel L. Association of the emerging carbapenemase NDM-1 with a blomycin resistance protein in Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother. 2012;56:1693–7. http://dx.doi.org/10.1128/AAC.00538-11

38. Chowdhury G, Pazhani GP, Nair GB, Ghosh A, Ramamurthy T. Transferable plasmid-mediated quinolone resistance in association with extended-spectrum β-lactamases and fluoroquinolone-acetylating aminoglycoside-6′-N-acetyltransferase in clinical isolates of Vibrio fluvialis. Int J Antimicrob Agents. 2011;38:169–73. http://dx.doi.org/10.1016/j.ijantimicag.2011.04.013

Address for correspondence: Thandavarayan Ramamurthy, Center for Human Microbial Ecology, Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad-Gurgaon Expressway, Faridabad 121001, Haryana, India; email: tramu@thsti.res.in